Abselion (HexagonFab Ltd.). (12/4/24). "Press Release: Abselion Raises £6.6 Million Led by M Ventures to Bring Disruptive At-line Protein Analyser, Amperia, to Market". Cambridge. - [MSC] Mass-Spec-Capital.com - The Mass Spectrometry Web Portal
Summary
Built on proprietary Redox Electrochemical Detection (RED) technology, Amperia brings a groundbreaking approach to biologics and viral-vector quantification for confident, convenient and cost-effective automated at-line measurement that is accessible to all laboratories and process environments.\xe2\x80\x9cWe are delighted to have the support of our investment partners to advance our mission to provide scientists with critical real-time data at the point of need,\xe2\x80\x9d says Ruizhi Wang, CEO of Abselion. We believe this will disrupt how Process Development operates today, and we invite our colleagues in the industry to reach out to me or the Abselion team to explore this further.\xe2\x80\x9d###Abselion is recruiting, if you are interested in joining the team, please visit our careers section!For media enquiries, please contact:Helen ManleyAbselioninfo@abselion.comAbout AbselionAbselion is a Cambridge, UK-based innovator in automated analytical instrumentation simplifying at-line protein analytics for the development and production of biologics, such as antibodies and viral vectors. Pioneering the highly sensitive and specific, Redox-Electrochemical-Detection (RED) technology, Abselion seeks to streamline and accelerate access to process insights in biopharmaceutical research, development and production. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs in the areas of healthcare drug development, life science tools, electronics and frontier technology & sustainability. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Mercks current and future businesses.